Skip to main content
SONOSCAPE MEDICAL CORP. logo

SONOSCAPE MEDICAL CORP. — Investor Relations & Filings

Ticker · 300633 ISIN · CNE100002P91 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2025-11-05 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300633

About SONOSCAPE MEDICAL CORP.

https://www.sonoscape.com

SonoScape Medical Corp. specializes in the research, development, and manufacturing of advanced medical diagnostic equipment. The company's primary product portfolio includes high-definition ultrasound systems, flexible endoscopy solutions, and electrocardiography devices. SonoScape focuses on delivering innovative imaging technology to healthcare providers globally, ranging from portable diagnostic tools to comprehensive trolley-based systems. Their ultrasound range covers various clinical applications such as cardiology, obstetrics, and radiology, while their endoscopy division provides high-resolution video processors and scopes for gastrointestinal and respiratory procedures. The company emphasizes continuous technological advancement and clinical efficiency to improve patient outcomes and diagnostic accuracy in diverse medical settings.

Recent filings

Filing Released Lang Actions
关于董事、高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholdings by company directors and senior management. It details the number of shares purchased, dates, prices, and compliance with relevant securities laws. It does not contain financial statements or performance data but focuses on insider share transactions by directors. This matches the definition of Director's Dealing (DIRS). The document length is short and specific to insider share transactions, confirming the classification.
2025-11-05 Chinese
关于2025年股票期权与限制性股票激励计划之股票期权授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Kaili Biomedical Technology Co., Ltd. regarding the completion of the registration of stock options granted under the 2025 stock option and restricted stock incentive plan. It details the approval process, the number of stock options granted, the recipients, the terms of the stock options, and the performance conditions for exercising the options. The document is a formal disclosure about the stock option grant event, including procedural approvals and specifics of the incentive plan. It is not a full financial report, earnings release, or management discussion, nor is it a proxy statement or remuneration report. It is a regulatory announcement about a capital incentive plan, specifically the stock option grant registration completion. This fits best under Capital/Financing Update (CAP) as it relates to company financing activities and equity incentives. The document length is over 5,000 characters and contains detailed substantive information about the stock option grant, not just a brief notice or report publication announcement.
2025-10-29 Chinese
关于2025年第三季度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (308 characters) from Shenzhen Kaili Biomedical Technology Co., Ltd. It states that the company's 2025 third quarter report was disclosed on a regulatory website and invites investors to review it. The text does not contain the actual financial data or detailed report content but merely informs about the report's publication. According to the 'Menu vs Meal' rule, such a brief notice about report disclosure is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2025-10-28 Chinese
第四届董事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Shenzhen Kaili Biomedical Technology Co., Ltd. It reports the approval of the company's 2025 third quarter report by the board of directors. The document states that the board reviewed and approved the Q3 report and that the report is disclosed on the official stock exchange information website. The document itself does not contain the full quarterly report or detailed financial statements but is an announcement of the board's approval and the meeting resolution. The document length is short (810 characters), and it references the actual quarterly report being available elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement related to the board meeting and report approval but does not contain the full interim/quarterly report itself.
2025-10-28 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '深圳开立生物医疗科技股份有限公司 2025 年第三季度报告' which translates to 'Shenzhen Kaili Biomedical Technology Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of accounting policy changes. The document explicitly states it is a quarterly report for the third quarter of 2025 and includes comprehensive financial statements and analysis. It also mentions that the report is unaudited. The length of the document (13,278 characters) and the detailed financial content confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-28 Chinese
第四届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Shenzhen Kaili Biomedical Technology Co., Ltd. It states that the Supervisory Board reviewed and approved the company's 2025 third quarter report, confirming the report's compliance and accuracy. However, the document itself does not contain the actual financial data or the full report; it only announces the approval and references the full report available on an external site. The document length is short (683 characters), and it serves as an announcement of the meeting resolution and the approval of the quarterly report, not the report itself. According to the 'Menu vs Meal' rule, this is a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR).
2025-10-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.